Zenas BioPharma, Inc.
ZBIO
$16.93
$0.613.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 100.00% | |||
| Cost of Revenue | 23.23% | -28.97% | |||
| Gross Profit | -72.70% | 43.58% | |||
| SG&A Expenses | -2.25% | 8.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.55% | -21.93% | |||
| Operating Income | -47.77% | 32.89% | |||
| Income Before Tax | -54.55% | 35.26% | |||
| Income Tax Expenses | 109.76% | -147.79% | |||
| Earnings from Continuing Operations | -55.55% | 36.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -55.55% | 36.18% | |||
| EBIT | -47.77% | 32.89% | |||
| EBITDA | -47.83% | 32.89% | |||
| EPS Basic | -55.30% | 35.97% | |||
| Normalized Basic EPS | -54.32% | 35.06% | |||
| EPS Diluted | -55.30% | 35.97% | |||
| Normalized Diluted EPS | -54.32% | 35.06% | |||
| Average Basic Shares Outstanding | 0.15% | -0.31% | |||
| Average Diluted Shares Outstanding | 0.15% | -0.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||